ISCK03 is primarily used in research settings as a selective antagonist of the angiotensin II type 2 (AT2) receptor. It is employed to study the physiological and pathological roles of the AT2 receptor in cardiovascular, renal, and neurological systems. Researchers use ISCK03 to investigate conditions such as hypertension, heart failure, and tissue injury, helping to differentiate AT2 receptor effects from those mediated by the AT1 receptor. Due to its selectivity, ISCK03 is a valuable tool in elucidating signaling pathways involved in cell growth, inflammation, and apoptosis. It is not used clinically but supports the development of targeted therapies by providing insights into AT2 receptor function.